Frost & Sullivan Independent Equity Research

Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9


Company: Cellect Biotechnology Ltd.        

Sector: Biotechnology

Report type: Quarterly Update, Q3

Published on: December 19, 2017

Cellect research articles:

Close Menu
Font Resize